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Heart failure is a progressive disease in which heart pump
dysfunction (heart failure with reduced ejection fraction,
HFrEF) or elevated left ventricular (LV) filling pressures
(heart failure with preserved ejection fraction) cause a
syndrome clinically represented by symptoms and signs
like breathlessness, fatigue, orthopnea, ankle swelling,
elevated jugular venous pressure, third heart sound,
pulmonary crackles.
Heart failure can be due to several causes such as myo-
cardial ischemia, valvular disease and abnormal heart
rhythms. Identifying the triggering causes is remarkably
important, not only for therapeutic strategies, but also for
the patient’s prognosis. Evidence-based therapies [such
as beta-blockers, angiotensin-converting enzyme inhibi-
tors (ACEis) or angiotensin II receptor blockers (ARBs),
mineralocorticoid receptor antagonists (MRAs), implant-
able cardioverter-difibrillator (ICD)/cardiac resynchroni-
zation therapy (CRT)] – which have been shown to
reduce morbidity and mortality – are available only for
HFrEF patients.1
Last but not least, a novel drug has been recently
approved for HFrEF patients who are still symptomatic,
namely sacubitril/valsartan, a combination of an angio-
tensin receptor blocker and a neprilysin inhibitor (which
interferes with the degradation of natriuretic peptides
and with the bradykinin system), finally resulting in an
enhanced natriuresis, reduced vasoconstriction, myocar-
dial relaxation and an antiremodeling effect.
The trial that led to its approval is PARADIGM – heart
failure.2
In the course of this trial, treatment with sacubitril/
valsartan proved to reduce mortality, hospitalizations
and patients’ symptoms. As is known, an important cause
of death among patients with HFrEF is sudden arrhyth-
mic death: despite only 16% of the study population
having an ICD, a reduction in mortality due to cardiovas-
cular death occurred anyway.
The patient is a 67-year-old male.
His clinical history is relevant for ischemic heart disease,
due to a previous anterior ST-elevation myocardial
infarction treated with coronary artery bypass graft
(1992) in particular the left internal mammary artery,
to bypass the left anterior descending artery.3–5
In 2006, the patient also had ICD implantation for
primary prevention in severely reduced ejection fraction
(30%).6
Despite the optimal medical therapy on top of the
treatment (candesartan 8mg/o.d., carvedilol 25mg/
b.i.d., canrenone 25mg/o.d., amiodarone 200mg/o.d.
and ivabradine 7.5mg/b.i.d.), and improvement of ejec-
tion fraction to 40%, during the last year several supra-
ventricular tachycardia and a few nonsustained
ventricular tachycardias (NSVT) were registered by the
device, and by ICD home monitoring.
Some of the supraventricular tachycardias had a 1 : 1
conduction, with an erroneous recognition and ATP
treatment by ICD.7
In particular, at the beginning of 2017 he had NSVT, so,
in March, during an outpatient ICD control, carvedilol
was titrated up to 25mg/b.i.d.
From March to June 2017, the patient had 16 tachyar-
rhythmias – 5 of which were very fast potential life-
threatening ventricular arrhythmias, which were treated
successfully by the ICD with ATP – whereas 11 were
supraventricular tachycardias, with 1 : 1 ventricular con-
duction, which ICD erroneously recognized as ventricu-
lar tachycardias. At this point, amiodarone 200mg/die was
introduced, but with poor success.
Indeed, in July 2017, the patient had 20 tachyarrhyth-
mias, in particular supraventricular tachycardias with 1 : 1
ventricular conduction, which the ICD erroneously rec-
ognized as ventricular fibrillation and treated incorrectly
(two of them with ATP); ivabradine 7.5mg/b.i.d. was
therefore introduced.
The patient’s ICD home monitoring showed that, from
July to September 2017, there were five other NSVTs,
four of them potential life-threatening ventricular
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arrhythmias treated with ATP (refer to the figure in
Annex: Boston report on arrhythmias).
Due to frequent arrhythmias his ejection fraction decreased
to 35%. So, after a coronarographic control (September
2017) that showed the absence of new coronary lesions,
the patient underwent an upgrade to atrioventricular node
modulation and upgrade to cardiac resynchronization ther-
apydefibrillators (CRT-D) (October 2017), despite anarrow
QRS (<120ms).
Despite this treatment, he was still symptomatic for
dyspnea, so sacubitril/valsartan treatment was started 4
months later (February 2018), the ejection fraction still at
35%. After 3 months of treatment, an improvement in the
symptoms and a significant reduction in both supraven-
tricular and ventricular tachyarrhythmias were observed,
while ejection fraction raised to 38%. At the last CRT-D
control (January 2018) the device registered only two
short runs of atrial flutter and no ventricular arrhythmias,
with a 100% biventricular pacing.
European Society of Cardiology guidelines on the treat-
ment of heart failure recently introduced sacubitril/val-
sartan for the treatment of HFrEF in those patients who,
despite an optimal medical therapy (ACEis/ARBs, beta-
blockers, MRAs, ICD), are still symptomatic.
The therapeutic effects of sacubitril/valsartan were
underlined by the PARADIGM-HF trial, which showed
how mortality is reduced in patients treated with this
drug. An analysis of the trial population showed that only
a low percentage of patients were ICD carriers (16%),
although – despite this – there was a significant 20%
reduction in sudden cardiac death.
Starting from this assumption, we cannot fail to include
our patient in this setting.
Our case deals with a patient with a history of severe LV
dysfunction, due to ischemic heart disease and concomi-
tant arrhythmic problems (atrial fibrillation, potential life-
threatening ventricular arrhythmias), the latter being per-
sistent, despite the maximum dosage of antiarrhythmic
therapy (amiodarone, carvedilol and ivabradine).8 In addi-
tion, the patient was still symptomatic for dyspnea and he
had also been hospitalized for heart failure, due to a
recurrent supraventricular tachycardia inappropriately
treated with the ICD intervention; sacubitril/valsartan
was therefore introduced, and after 3 months a significant
reduction in both supraventricular and ventricular arrhyth-
mias was registered, despite nothing having been changed
in his antiarrhythmic therapy. The only exception was the
upgrading to CRT-D, which could prevent ventricular
arrhythmias by biventricular pacing and reverse remodel-
ing. The latter is not our case, since CRT was implanted
not to resynchronize the ventricles (being QRS narrow),
but to avoid desynchronization by continuous right ven-
tricular pacing. Consequently, his ejection fraction did not
change after 4 months of CRT therapy. However, we
acknowledge that biventricular pacing could contribute
to ventricular arrhythmias reduction.
The things we noted in this patient we had observed in a
larger set of patients with overlapping features. A recent
trial by de Diego et al.9 collected data from 120 patients
with ICD and severe LV dysfunction (ejection fraction
<40%) being treated with optimal medical therapy and
sacubitril/valsartan. Patients were followed for 9 months,
with analyses of the arrhythmic events and ICD inter-
vention therapies. The authors found that adding sacu-
bitril/valsartan to the standard optimal medical therapy
for heart failure significantly reduce nonsustained ven-
tricular tachycardia, sustained ventricular tachycardia and
appropriate ICD shocks; there was also an increase in
biventricular pacing, due to a reduction in premature
ventricular contraction (PVC)/h. In the course of this trial,
supraventricular tachyarrhythmias – including the inci-
dence of atrial fibrillation and the consequent inappro-
priate intervention of the ICD – were also reduced,
although without reaching any statistical significance.
From our experience, and from the aforementioned trial,
we can deduce that sacubitril/valsartan could have anti-
arrhythmic properties. Also the deremodeling effect of
the drug can contribute to the reduction of the arrhythmic
burden: in our patient ejection fraction raised from 35 to
38% thanks to the new drug. Future studies are needed to
better investigate this issue.
Some possible mechanisms to explain this finding could
be the following:
(1) The blockage of natriuretic peptides (NPs) degrada-
tion is by itself an important predictor of ventricular
tachycardias and ICD shocks; NPs can also decrease
the sympathetic activity (trigger for tachyarrhyth-
mias), much more that enalapril alone can do.10–12
(2) The natriuretic effect of sacubitril/valsartan allows
the diuretic dosage to be reduced, with a lower risk of
hypokalemia, which in turn is responsible for
ventricular tachycardias.13
(3) Sacubitril/valsartan could have reverse remodeling
properties which lead to LV ejection fraction
improvement.
(4) Sacubitril/valsartan-induced natriuresis reduces
the volume overload causing myocardial stretch,
which in turn is a trigger of PVC and ventricular
tachycardia.14,15
(5) Reducing PVC also increases biventricular pacing,
which improves the cardiac function.16
(6) A repetitive myocardial stretch can induce fibrosis
and electrophysiological remodeling, a triggering
element for the occurrence and persistence of
arrhythmias.17,18
Even if the reduction in tachyarrhythmias, due to sacu-
bitril/valsartan, is an enticing option, we should not
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ignore that in the PARADIGM-HF study there was no
difference between the two groups, with regard to the
onset of atrial fibrillation.
We think that the putative antiarrhythmic properties of
sacubitril/valsartan should be studied in greater detail,
using patients on optimal medical therapies, including
antiarrhythmic drugs and implantable devices that can be
controlled in an outpatient setting or remotely.
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